Cambridge, UK; 19th October 2021. For Immediate Release

Atlantic Healthcare plc, a specialist pharmaceutical company, confirms that its CEO, Toby Wilson Waterworth, will speak at the Middle East Investor Relations Association (MEIRA) Annual Conference in Dubai on 25 October, UAE, and attend the Future Investment Initiative (FII) in Riyadh, Saudi Arabia on 26-28 October.

Atlantic Healthcare focuses on acquiring, developing, and commercializing therapies that address unmet patient needs in gastroenterology (GI) and rare diseases.

If you’re attending these events and would like to meet Toby, please contact him via [email protected] or the details at the end of this PRL.

Middle East Investor Relations Association (MEIRA) Annual Conference & Awards
The MEIRA conference is the largest IR event in MENA and brings together listed firms, international corporations, investors, research analysts and advisors, as well as representatives of the region’s regulatory bodies.
Date: 25th October 2021
Time: 14:20 – 15:00 (GST)
For more information about the MEIRA Conference, please visit

Future Investment Initiative (FII) 5th Anniversary – Invest in Humanity
The Future Investment Initiative is a platform driven by expert-led debates, discussions, and partnerships among the world’s most influential leaders in business and government. For the past five years, the ​FII community has shaped the future of global investment through an interactive program featuring conversations with global leaders, executive roundtables, and networking among CEOs and policymakers.
Dates: 26th – 28th October 2021

For more information about the Future Investment Initiative, please visit

~ ENDS ~

About Atlantic Healthcare
Atlantic Healthcare plc ( is a specialist pharmaceutical company focused on acquiring, developing, and commercializing therapeutics that address unmet patient needs in gastroenterology (GI) and rare diseases.

The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug in development for ulcerative colitis and Crohn’s disease, and renzapride, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders, including patients with Cystic Fibrosis and Systemic Scleroderma.

Led by an experienced international board and leadership team who have deep roots and a proven track record in the pharmaceutical industry, Atlantic Healthcare is commercializing its products itself in the U.S. and Europe and through partnerships and licensing with established pharmaceutical companies in the rest of the world.

Forward Looking Statements
While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.